BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• TTP Plc And Sphere Fluidics Introduce Cyto-Mine Single Cell Analysis System

  TTP Plc today announced the launch of the award-winning Cyto-Mine Single Cell Analysis System. Recently awarded a Frost and Sullivan award for Product Innovation.

  October 17, 2017

   · 

  3 min read
• Deals

  MabVax Provides Corporate Overview, Business Outlook

  The company provided a corporate overview and business outlook for the remainder of 2017.

  October 17, 2017

   · 

  10 min read
• Business

  Syndax Expands Pipeline with Exclusive Worldwide License to Allergan’s Portfolio of Menin-MLL Inhibitors

  Syndax today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharma for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the MLL protein.

  October 17, 2017

   · 

  5 min read
• FDA

  Second Sight Receives Approval in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis Pigmentosa Patients

  Second Sight will begin a 10-patient study to implant and evaluate the Argus II Retinal Prosthesis System in better sighted retinitis pigmentosa patients.

  October 17, 2017

   · 

  6 min read
• Business

  Acerus Announces Licensing Of NATESTO In South East Asian Countries

  Acerus Pharmaceuticals today announced the signing of an agreement granting Eu Hwa Pte LTD. (“EU”) the exclusive right to market NATESTO in Thailand, Malaysia/Brunei, Singapore, Vietnam, Philippines, Hong Kong/Macau and one other small South East Asian country.

  October 17, 2017

   · 

  4 min read
• Policy

  US FDA Accepts Supplemental Biologics License Application For IMFINZI (Durvalumab) In Locally Advanced, Unresectable Non-Small Cell Lung Cancer

  AstraZeneca and MedImmune today announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) for the treatment of patients with locally advanced.

  October 17, 2017

   · 

  15 min read
• Medigus Receives First Purchase Order From Izasa Hospital in Spain for Its MUSE System

  Medigus announced that Izasa Hospital, S.L.U., a distributor of medical products in the hospital sector, has provided an initial purchase order (PO) for the Medigus Ultrasonic Surgical Endostapler, or MUSE system.

  October 17, 2017

   · 

  4 min read
• Drug Development

  MiMedx Notified By FDA That It Can Proceed With Phase IIB Investigational New Drug Clinical Trial For Osteoarthritis Of The Knee

  MiMedx announced today that the Company has been notified by the FDA that its IND Phase 2B clinical study for osteoarthritis of the knee may proceed.

  October 17, 2017

   · 

  5 min read
• Drug Development

  ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease

  ProMIS Neurosciences today announced that its lead product candidate for Alzheimer’s disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer’s disease (AD).

  October 17, 2017

   · 

  3 min read
• Policy

  Charleston Laboratories Resubmits NDA for CL-108

  Charleston Labs announced today that it resubmitted the NDA for its novel investigational treatment, CL-108, for the relief of moderate to severe acute pain while preventing and reducing opioid-induced nausea and vomiting (OINV) for patients with pain severe enough to require an opioid.

  October 17, 2017

   · 

  4 min read